اعلنت الشركة انها حصلت ع براءة اختراع ف المكسيك ... وبالتالي حصلت ع 71 براءة اختراع Generex Biotechnology Receives Patent in Mexico
Thursday March 16, 9:00 am ET
Company Expands Drug Delivery Platform Patent Portfolio
TORONTO--(MARKET WIRE)--Mar 16, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News), a leader in the area of buccal drug delivery, announced today that it has been granted a patent by the Mexico National Registry of Patents titled "Proteinic Drug Delivery System Using Aerosolized Membrane-Mimetic Amphiphiles." The patent, an extant United States Patent registered by the Company, relates to an improved delivery system for the administration of large-molecule pharmaceuticals, particularly through the oral and nasal membranes.
ADVERTISEMENT
The patent covers formulations for the delivery of peptidic drugs, vaccines, and hormones and enhances the Company's existing drug delivery platform patent portfolio.
"We are pleased to augment our Latin American patent protection as we continue with our Generex Oral-lyn(TM) commercialization efforts in the region," said Rose Perri, the Company's Chief Operating Officer. Generex Oral-lyn is the Company's flagship product, a proprietary oral insulin spray product which has been approved by the Ecuadorian Ministry of Public Health for the treatment of Type-1 and Type-2 diabetes.
The Company currently holds an aggregate of 71 patents (19 of which are United States patents) and has an aggregate 58 patent applications pending in various jurisdictions.